News >

Jagannath Discusses Building on the Biology of Multiple Myeloma

Caroline Seymour
Published: Monday, Dec 17, 2018

Sundar Jagannath, MD

Sundar Jagannath, MD
Understanding the proliferation of malignant myeloma cells can only be discerned by going back to the biology of the disease, explained Sundar Jagannath, MD, and greater understanding of a patient’s cytogenetics may compound the success seen with chemotherapy and novel adoptive cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapy.

during the 2018 State of the Science Summit™ on Multiple Myeloma, Jagannath, director of the Multiple Myeloma program and professor of Medicine at the Tisch Cancer Institute, Mount Sinai Health System, provided insight into the biology of multiple myeloma.

OncLive: How can the biology of myeloma inform the management of newly diagnosed disease?

Jagannath: There are 2 founder clones in myeloma. One is hyper-deployed and another one is nonhyper-deployed; these founder clones multiply over the years. During that time, they undergo additional mutations that gives them growth advantage. By the time a patient is diagnosed with multiple myeloma, they have 1 of these founder clones that has spread and acquired many mutations. Each patient has at least 4 to 6 different clones in the body.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication